Skip to main content
Book Chapter

Ropinirole in the Treatment of Parkinson’s Disease

Springer International Publishing, (2022), 3285-3292
DOI: 10.1007/978-3-030-62059-2_235
0Citations
Citations of this article
2Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Ropinirole is a synthesized non-ergotamic dopamine receptor agonist. It has an affinity to D2 and D3 dopamine receptors. It also has a partial affinity to 5-HT1a receptor as pramipexole. The affinity of ropinirole to the D3 receptor is 20 times larger compared to the D2 receptor. It does not have an affinity to the D1 receptor.

Cite

CITATION STYLE

APA

Konaka, K., & Mochizuki, H. (2022). Ropinirole in the Treatment of Parkinson’s Disease. In NeuroPsychopharmacotherapy (pp. 3285–3292). Springer International Publishing. https://doi.org/10.1007/978-3-030-62059-2_235

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free